Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial

Assenat, E; Pageaux, GP; Thezenas, S; Peron, JM; Becouarn, Y; Seitz, JF; Merle, P; Blanc, JF; Bouche, O; Ramdani, M; Poujol, S; de Forges, H; Ychou, M; Boige, V

Assenat, E (reprint author), Univ Montpellier, ICM, Montpellier, France.; Assenat, E (reprint author), Univ Montpellier, CHU Montpellier, Montpellier, France.

BRITISH JOURNAL OF CANCER, 2019; 120 (9): 896

Abstract

BACKGROUND: Sorafenib remains one major first-line therapeutic options for advanced hepatocellular carcinoma (aHCC), with modest efficacy. We investig......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索